THE COST-EFFECTIVENESS OF IVF TREATMENTS GONAL-F® VERSUS HP-HMG IN THE UNITED ARAB EMIRATES (UAE)
Author(s)
Elkalyoubi M1, Garg N2, Eladly Farag T3, Fakih A4, Jain R2, Madkour W1, Noah B5, Prasanna R6, Sayed W7, Wadie G3, Zaheer H1, van Gils C8
1Dubai gynaecology & fertility center, Dubai, United Arab Emirates, 2QuintilesIMS, Gurgaon, India, 3Merck Serono Middle East FZ-LLC, Dubai, United Arab Emirates, 4Fakih IVF, Dubai, United Arab Emirates, 5Conceive - Gynaecology & Fertility Hospital, Sharjah, United Arab Emirates, 6QuintilesIMS, Jeddah, United Arab Emirates, 7HealthPlus Fertility & Women's Health Center, Abu Dhabi, United Arab Emirates, 8QuintilesIMS, Zaventem, Belgium
OBJECTIVES: In the UAE, infertility rate is about 2.2%, with growing incidence. In-vitro fertilization (IVF) is one of the commonly used techniques in the UAE for the management of infertility. This study assessed the cost-effectiveness of recombinant human follicle-stimulating hormone (rFSH, Gonal-f®) with highly purified human menopausal gonadotrophin (HP-hMG) for ovarian stimulation in IVF treatment in the UAE. METHODS: A decision tree combined with a Markov model was developed, simulating each step in the IVF protocol from the start of therapy until either live born, new IVF treatment cycle, or stopping IVF (ovum pickup, fertilization, embryo transfer and life born). Differentiation between Gonal-f and HP-hMG was based on a published meta-analysis. Three settings were considered that included 1) fresh transfer only, 2) combined fresh transfer and freeze oocytes, and 3) combined fresh transfer and freeze embryos. Costs are listed as 2016 AED. The model was validated by expert gynecologists from the UAE RESULTS: Gonal-f® was cost-effective over HP-hMG with lower average treatment costs and higher live births per patient in all three settings. In setting 1 average treatment cost was estimated at 51,935 for Gonal-f® and AED 52,371 for HP-hMG® was 0.235 versus 0.233 with HP-hMG. In setting 2, these costs were AED 55,715 and AED 56,142, for Gonal-f® and HP-hMG, along with increased probability of live born (0.243 and 0.241, respectively). Setting 3 had lowest average treatment cost of AED 48,080 and AED 48,822 and highest probability of live born, 0.307 and 0.303, for Gonal-f® and HP-hMG, respectively. Sensitivity analysis showed the robustness of the results. CONCLUSIONS: Gonal-f® may represent a cost-effective option compared with HP-hMG for ovarian stimulation for IVF treatment in the UAE.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PIH16
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Reproductive and Sexual Health